Update on the Treatment of Metastatic Urothelial Carcinoma

Table 2

Immunotherapy trials [11].

Setting	Drug	Study	No. of patients	ORR %	ORR (%) by PD-L1; Subgroup (high/low)	PD-L1 High +ve; Prevalence (%)
Post platinum	Atezolizumab	IMvigor210	310	15	26 (IC 2/3) 32	32
					9 (IC 0/1)
	Nivolumab	Checkmate 275	270	19.6	28.4 (TC ≥ 5%)	30
					16.1 (TC< 1%)
	Pembrolizumab	KEYNOTE 045	542	21	21.6 (CPS ≥ 10%)	30
					NR
	Durvalumab	Study 1108	103	20	31 (TC or IC ≥ 25%)	59
					5 (TC and IC< 25%)
	Avelumab	JAVELIN	44	18	53.8 (TC ≥ 5%)	35
					4.2 (TC < 5%)
Cisplatin ineligible	Atezolizumab	IMvigor210	119	23	28 (IC 2/3)	27
					21 (IC 0/1)
	Pembrolizumab	KEYNOTE 052	370	24	39 (CPS ≥ 10%)	35

Abbreviations. CPS: combined positive score (assesses PD-L1 expression as a composite of both IC and TC expression); IC: immune cell; NR: not reported; ORR: objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; PD-L1: programmed death receptor ligand-1; TC: tumor cell. CPS ≥ 10% as an expression cutoff was defined in the first 100 patients; the ORR of 39% is reported for the validation set of the remaining 270 patients enrolled.